|Day Low/High||218.25 / 224.28|
|52 Wk Low/High||170.56 / 244.99|
TheStreet's Jim Cramer discusses Wednesday's trending stocks.
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Why the name is sagging, and what it will take to spur the sector higher.
Jim Cramer says no one really knows what President Trump means when it comes to drug pricing.
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
The 50-day moving average is crossing the 200-day for a bullish golden cross; go long here.
Some tried-and-true indicators show what's really going on with the market.
Would get drugs to market faster and possibly more cheaply.
The Fed is simply not a market catalyst this time.
There's not much reason to be bullish on these stocks.
Nike, Disney and Amgen shares struggled in 2016. Here is why they are ready to rebound in 2017.
Apple could be the biggest winner if the Trump administration grants U.S. companies a repatriation tax holiday.
The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.
The Dow Jones Industrial Average came agonizingly close to its 20,000 milestone before falling short and backing off.
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
Traders could buy a dip to $150 if available or they can buy strength above $155, which ever comes first.
My trade of the year for 2017 is to short the PowerShares QQQ Trust ETF , which tracks the Nasdaq 100 index. Here's my investment thesis for this play: The Nasdaq 100 Already Has Rallied QQQ already has risen from about $96 a share at the market's F...
It's got several newly launched promising drugs, a number of late-stage prospects and strong financials.
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...